相关实验视频

Updated: Jul 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

在转移性尿路细胞癌中治疗erdafitinib:现实世界的分析

Keren Rouvinov^1,2, Eran Levanon³, Avivit Peer⁴

¹The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva, Israel.

Frontiers in oncology

|June 9, 2023

概括

现实数据显示,erdafitinib在转移性尿路细胞癌患者中具有FGFR变异的患者提供了临床益处. 观察到的毒性与临床试验相似,有56%的人经历了益处,52%的人报告了3级毒性.

科学领域:

在瘤学瘤学.
生殖尿道癌症生殖尿道癌症
药理学药理学是指药理学的学科.

背景情况:

埃尔达菲提尼布是一种FGFR抑制剂,用于转移性尿路细胞癌与FGFR2/3变异.
根据第二阶段试验获得批准,但由于不常见的基因组变化,其现实数据有限.
这项研究评估了在现实世界患者队列中的erdafitinib结果.

研究的目的:

评估erdafitinib在转移性尿路细胞癌的现实环境中的疗效和安全性.
将现实世界的结果与未来临床试验的结果进行比较.

主要方法:

在以色列9个医疗中心对25名接受了herdafitinib治疗的患者进行了回顾性审查.
从2020年1月到2022年10月收集的数据.
分析包括临床益处,无进展生存率,总生存率和与治疗相关的毒性.

主要成果:

56%的患者获得了临床益处,包括完全响应 (12%) 和部分响应 (32%).
中位数无进展生存期为2.7个月,中位数整体生存期为6.73个月.
高度的3级毒性 (52%) 导致32%的患者停止治疗.

结论:

埃尔达菲提尼布在现实世界转移性尿路细胞癌治疗中显示出临床益处.
在现实世界中使用的毒性概况与前性临床试验的发现保持一致.
需要进一步研究在不同患者群体中管理herdafitinib毒性.

关键词:

赫达菲提尼布 (herdafitinib) 是一种药物.纤维细胞生长因子受体 (FGFR) 抑制剂转移性尿路细胞癌癌.现实世界的分析分析.治疗治疗治疗治疗治疗治疗

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...